A carregar...
Outcome of COVID-19 patients with use of Tocilizumab: A single center experience
COVID-19 pandemic has become a global concern. Cytokine release syndrome (CRS) complicates acute respiratory distress syndrome (ARDS) and causes multi-organ failure which can subsequently lead to mortality in COVID-19 patients. Tocilizumab, an interleukin-6 antagonist, has shown to salvage patients...
Na minha lista:
| Publicado no: | Int Immunopharmacol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elsevier B.V.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7455148/ https://ncbi.nlm.nih.gov/pubmed/32889236 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.intimp.2020.106926 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|